Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal up6.080 +0.030 (+0.496%)

01/09/2021 17:56

Sino Biopharm (01177) gets drug registration certificate

[ET Net News Agency, 1 September 2021] Sino Biopharmaceutical Limited (01177) said
"Sofosbuvir Tablets" (brand name: Suoweidi), a new antiviral drug developed by the group,
has obtained drug registration certificate granted by the National Medical Products
Administration of the PRC, being the second generic drug of its kind that has obtained
approval for drug registration in the PRC, and is deemed to have passed the Consistency of
Quality and Efficacy Evaluation for Generic Drugs.
Sofosbuvir is used for the treatment of Chronic Hepatitis C Virus (HCV) infection as it
has the characteristic of pan-genotypic efficacy, high clinical recovery rate, easy
medication, no significant side effects, low incidence of virus resistance, and high
safety and effectiveness on patients with severe liver disease. The introduction of
Sofosbuvir makes Hepatitis C become a clinical completely curable disease. Currently,
various new domestic and international guidelines have recommended Sofosbuvir as the
firstline treatment for Hepatitis C. (RC)

Remark: Real time quote last updated: 21/01/2022 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.